Treatment Options in Patients with Chronic Hepatitis C

作者: Samuel S Lee , Kelly W Burak

DOI: 10.17269/CJPH.91.1424

关键词:

摘要: Hepatitis C is a major health care problem plagued by the lack of truly effective therapy. To date, combination interferon and ribavirin has provided best chance viral eradication. However, this therapy expensive, multiple side effects works in less than half patients. New strategies need to be developed deal with increasing burden hepatitis C-related disease, we anxiously await arrival new drugs such as helicase protease inhibitors.

参考文章(49)
L Cimino, G Budillon, M Podda, C Loguercio, G Ideo, C Del Vecchio Blanco, G Raimondo, A Crosignani, R Stabilini, Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepato-gastroenterology. ,vol. 45, pp. 1624- 1629 ,(1998)
Solko W Schalm, Bettina E Hansen, Liliana Chemello, Antonio Bellobuono, Johannes T Brouwer, Ole Weiland, Luisa Cavalletto, Robert Schvarcz, Gaetano Ideo, Alfredo Alberti, None, Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers Journal of Hepatology. ,vol. 26, pp. 961- 966 ,(1997) , 10.1016/S0168-8278(97)80103-1
KATSUAKI TANAKA, MASAAKI KONDO, TAKASHI SAKAGUCHI, SATORU SAITO, SHINJU ARATA, MASANORI IKEDA, TAKEHIKO KITAMURA, MANABU MORIMOTO, HISAHIKO SEKIHARA, Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. Journal of Gastroenterology and Hepatology. ,vol. 11, pp. 1155- 1160 ,(1996) , 10.1111/J.1440-1746.1996.TB01844.X
Thierry Poynard, John McHutchison, Zachary Goodman, Mei-Hsiu Ling, Janice Albrecht, Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. ,vol. 31, pp. 211- 218 ,(2000) , 10.1002/HEP.510310131
Geoffrey Dusheiko, Janice Main, Howard Thomas, Olle Reichard, Christine Lee, Amar Dhillon, Suhra Rassam, Aril Fryden, Henk Reesink, Margaret Bassendine, Gunnar Norkrans, Theo Cuypers, Nico Lelie, Paul Telfer, Jon Watson, Christine Weegink, Peter Sillikens, Ola Weiland, Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study Journal of Hepatology. ,vol. 25, pp. 591- 598 ,(1996) , 10.1016/S0168-8278(96)80225-X
Fabris, Tositti, Negro, Marranconi, Infantolino, Rassu, De Lalla, Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Alimentary Pharmacology & Therapeutics. ,vol. 13, pp. 1329- 1334 ,(1999) , 10.1046/J.1365-2036.1999.00613.X
William G Bennett, Yuji Inoue, J Robert Beck, John B Wong, Stephen G Pauker, Gary L Davis, Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C Annals of Internal Medicine. ,vol. 127, pp. 855- 865 ,(1997) , 10.7326/0003-4819-127-10-199711150-00001
E. Jenny Heathcote, Emmet B. Keeffe, Samuel S. Lee, Saya V. Feinman, Myron J. Tong, K. R. Reddy, Karsten Witt, Lawrence M. Blatt, , Re-treatment of chronic hepatitis C with consensus interferon . Hepatology. ,vol. 27, pp. 1136- 1143 ,(1998) , 10.1002/HEP.510270431
R L Carithers, S S Emerson, Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials Hepatology. ,vol. 26, ,(1997) , 10.1002/HEP.510260715
Y Shiratori, N Kato, O Yokosuka, F Imazeki, E Hashimoto, N Hayashi, A Nakamura, M Asada, H Kuroda, N Tanaka, Y Arakawa, M Omata, Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group Gastroenterology. ,vol. 113, pp. 558- 566 ,(1997) , 10.1053/GAST.1997.V113.PM9247476